This product is a CRISPR/Cas9-edited polyclonal CASP3 knockout cell population derived from the NCI-H1299 non-small cell lung carcinoma (NSCLC) cell line. The polyclonal composition represents a heterogeneous pool of cells carrying targeted disruptions of the CASP3 gene, generated via CRISPR/Cas9-mediated genome editing. This loss-of-function model eliminates full-length caspase-3 protein expression, providing a robust system for investigating caspase-3-dependent apoptotic mechanisms without clonal selection artifacts.
NCI-H1299 is a widely utilized human cell line isolated from a lymph node metastasis of a lung adenocarcinoma. These cells are p53-deficient, a characteristic that impairs DNA damage-induced apoptosis and contributes to their tumorigenic and metastatic properties. The p53-null background makes NCI-H1299 particularly valuable for cancer research, especially for studies exploring apoptosis evasion, chemoresistance, and signal transduction in advanced lung carcinoma.
CASP3 encodes caspase-3, the principal executioner caspase that orchestrates the final stages of apoptotic cell death. Caspase-3 is activated by upstream initiator caspases through two main pathways: extrinsic signaling via death receptors (e.g., FasL/TRAIL) that activate CASP8 and CASP10, and intrinsic signaling involving cytochrome c release, APAF1 apoptosome formation, and CASP9 activation. Once activated, caspase-3 cleaves numerous cellular substrates, including PARP1, DFFA (ICAD), lamin A, gelsolin, and ROCK1, leading to DNA fragmentation, nuclear disassembly, and cytoskeletal collapse. Its activity is tightly regulated by inhibitor proteins such as XIAP and Survivin (BIRC5), while indirect modulation occurs through Bcl-2 family-mediated mitochondrial permeabilization and c-FLIP control of death receptor signaling.
In the context of p53-deficient NCI-H1299 cells, CASP3 knockout creates a powerful platform to dissect caspase-3-dependent and -independent cell death modalities. Since these cells lack functional p53, apoptosis induction often relies on alternative pathways or bypass mechanisms. Eliminating caspase-3 allows researchers to probe the contributions of other executioner caspases, assess non-apoptotic cell death forms, and evaluate the efficacy of chemotherapeutic agents that may operate through p53-independent routes. This model is particularly relevant to non-small cell lung cancer, where apoptosis resistance is a hallmark of disease progression and therapeutic failure.
This polyclonal knockout cell population enables a wide array of experimental applications, including detailed apoptosis signaling studies, screening for drug resistance mechanisms, and identification of caspase-3-independent death pathways. Typical assays include western blotting for caspase-3 and PARP cleavage, Annexin V/propidium iodide flow cytometry, caspase-3 enzymatic activity measurements, cytochrome c release analyses, TUNEL staining, and various cell viability assessments. It is also suitable for functional genomics and chemotherapeutic agent testing, facilitating the discovery of novel therapeutic targets in metastatic lung adenocarcinoma. For more information or technical support, please contact Ascent Research.
